Subbiah, V., Berry, J., Roxas, M., Guha-Thakurta, N., Subbiah, I. M., Ali, S. M., . . . Heymach, J. V. (2015). Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged Non-Small Cell Lung Cancer with brain metastases. Lung Cancer.
Chicago Style CitationSubbiah, Vivek, et al. "Systemic and CNS Activity of the RET Inhibitor Vandetanib Combined With the MTOR Inhibitor Everolimus in KIF5B-RET Re-arranged Non-Small Cell Lung Cancer With Brain Metastases." Lung Cancer 2015.
Cita MLASubbiah, Vivek, et al. "Systemic and CNS Activity of the RET Inhibitor Vandetanib Combined With the MTOR Inhibitor Everolimus in KIF5B-RET Re-arranged Non-Small Cell Lung Cancer With Brain Metastases." Lung Cancer 2015.